NCT01486329View on ClinicalTrials.gov

VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

October 31, 2014

Study Completion Date

December 31, 2014

Conditions
Stage IV Pancreatic Cancer
Interventions
BIOLOGICAL

VXM01

Live anti-angiogenic cancer vaccine drink solution, escalating dose

BIOLOGICAL

Placebo

Drink solution

Trial Locations (1)

69120

Clinic of General Surgery, Heidelberg

All Listed Sponsors
lead

Vaximm GmbH

INDUSTRY

NCT01486329 - VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer | Biotech Hunter | Biotech Hunter